|
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction (PR Newswire via Yahoo! Finance)
Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.
us.rd.yahoo.com
My Pharmiweb.com (PharmiWeb)
INDIANAPOLIS, Sept 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ Eli Lilly and Company (NYSE: LLY) announced today it received approval from the U.S. Food and Drug Administration (FDA) for the use of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with ...
us.rd.yahoo.com
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval (PR Newswire via Yahoo! Finance)
Eli Lilly and Company announced today it received approval from the U.S. Food and Drug Administration for the use of ALIMTA® , in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer , for patients with nonsquamous histology.
us.rd.yahoo.com
'Industrial Manslaughter,' Immediate Action Needed For Prevention, Says Expert (Medical News Today)
Jeanne Mager Stellman, PhD, professor and chair of environmental and occupational health sciences at SUNY Downstate Medical Center, told the President's Cancer Panel that government policy and a "lack of the will to prevent occupational disease, death and disability" are responsible for the failure to control cancer-causing chemicals in the workplace.
us.rd.yahoo.com
Immediate Action Needed to Prevent 'Industrial Manslaughter,' Says Expert (Newswise)
Dr. Jeanne Stellman tells Presidential Panel that many chemicals remain unregulated.
us.rd.yahoo.com
|
